Friedreich Ataxia - Pipeline Review, H1 2017

Publisher Name :
Date: 11-Apr-2017
No. of pages: 85
Inquire Before Buying

Friedreich Ataxia - Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H1 2017, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape.

Friedreich's ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down through a family. Signs and symptoms include ataxia, weakness and spasticity, sensory impairment, skeletal abnormalities, cardiac difficulties and diabetes.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Friedreich Ataxia - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Friedreich Ataxia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Friedreich Ataxia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Friedreich Ataxia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 4, 2, 13 and 3 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 1 and 2 molecules, respectively.

Friedreich Ataxia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Friedreich Ataxia (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Friedreich Ataxia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Friedreich Ataxia (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Friedreich Ataxia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Friedreich Ataxia (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Friedreich Ataxia (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Friedreich Ataxia (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Friedreich Ataxia - Pipeline Review, H1 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Friedreich Ataxia - Overview
Friedreich Ataxia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Friedreich Ataxia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Friedreich Ataxia - Companies Involved in Therapeutics Development
Adverum Biotechnologies Inc
BioMarin Pharmaceutical Inc
Biovista Inc
Cardero Therapeutics Inc
Catabasis Pharmaceuticals Inc
Edison Pharmaceuticals Inc
Forward Pharma A/S
Ixchel Pharma LLC
Pfizer Inc
ProQR Therapeutics NV
RaNA Therapeutics Inc
Reata Pharmaceuticals Inc
Retrotope Inc
Shire Plc
STATegics Inc
Voyager Therapeutics Inc
Friedreich Ataxia - Drug Profiles
ADVM-063 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AGIL-FA - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVA-202 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BVA-203 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAT-4001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cell Therapy for Central Nervous System and Neurodegenerative Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTI-1601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dextro epicatechin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dimethyl fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Frataxin for Friedreich's Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Frataxin for Friedrich's Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
interferon gamma-1b - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IXC-105 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JOT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oligonucleotide to Activate Frataxin for Friedreich's Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
omaveloxolone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
QRX-604 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein 1 to Replace FXN for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-3250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RT-002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-622 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Activate Frataxin for Friedreich Ataxia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STSE-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vatiquinone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VYFXN-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Friedreich Ataxia - Dormant Projects
Friedreich Ataxia - Discontinued Products
Friedreich Ataxia - Product Development Milestones
Featured News & Press Releases
Nov 17, 2016: Catabasis Pharmaceuticals Provides Update on Rare Disease Program CAT-4001 at Investor Day
Aug 02, 2016: Agilis Biotherapeutics Announces FDA Orphan Drug Designation for the Treatment of Friedreich's Ataxia
Jan 19, 2016: FARA Announces Catabasis Pharmaceuticals as the Recipient of the Kyle Bryant Translational Research Award to Evaluate CAT-4001 as a Potential Therapy for Friedreich's Ataxia
Aug 05, 2015: Key Patent Granted For AAVLife's Gene-Therapy Program to Treat Cardiomyopathy in Friedreich's Ataxia
Mar 24, 2015: Catabasis Pharmaceuticals to Present at International Ataxia Research Conference
Mar 17, 2014: FDA Awards Fast Track Status to Edison Pharmaceuticals' EPI-743 for Friedreich's Ataxia
Feb 04, 2014: FDA Grants Edison Pharmaceuticals' EPI-743 Orphan Status for Friedreich's Ataxia
Nov 04, 2013: Edison Pharmaceuticals, FARA, and USF Announce Initiation of EPI-743 Phase 2 Friedreich's Ataxia Clinical Trial in Adults with Point Mutations
Jan 07, 2013: Edison Pharma Initiates Phase IIb Clinical Trial Of EPI-743 In Friedreich Ataxia
Aug 01, 2012: Intellect Neurosciences Receives New Patent Allowance For OX1
Aug 02, 2011: STATegics, Inc. Announces a Grant from Friedreich's Ataxia Research Alliance to Support Its Program to Develop Small Molecule Mimetics of Erythropoietin for the Treatment of Friedreich's Ataxia
Apr 12, 2011: Intellect Neurosciences Files Orphan Drug Application In US For OX1 In Friedreich's Ataxia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Friedreich Ataxia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Friedreich Ataxia - Pipeline by Adverum Biotechnologies Inc, H1 2017
Friedreich Ataxia - Pipeline by BioMarin Pharmaceutical Inc, H1 2017
Friedreich Ataxia - Pipeline by Biovista Inc, H1 2017
Friedreich Ataxia - Pipeline by Cardero Therapeutics Inc, H1 2017
Friedreich Ataxia - Pipeline by Catabasis Pharmaceuticals Inc, H1 2017
Friedreich Ataxia - Pipeline by Edison Pharmaceuticals Inc, H1 2017
Friedreich Ataxia - Pipeline by Forward Pharma A/S, H1 2017
Friedreich Ataxia - Pipeline by Ixchel Pharma LLC, H1 2017
Friedreich Ataxia - Pipeline by Pfizer Inc, H1 2017
Friedreich Ataxia - Pipeline by ProQR Therapeutics NV, H1 2017
Friedreich Ataxia - Pipeline by RaNA Therapeutics Inc, H1 2017
Friedreich Ataxia - Pipeline by Reata Pharmaceuticals Inc, H1 2017
Friedreich Ataxia - Pipeline by Retrotope Inc, H1 2017
Friedreich Ataxia - Pipeline by Shire Plc, H1 2017
Friedreich Ataxia - Pipeline by STATegics Inc, H1 2017
Friedreich Ataxia - Pipeline by Voyager Therapeutics Inc, H1 2017
Friedreich Ataxia - Dormant Projects, H1 2017
Friedreich Ataxia - Discontinued Products, H1 2017

List of Figures
Number of Products under Development for Friedreich Ataxia, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017
  • Global Infertility Treatment Market Analysis By Procedure (ART, Artificial Insemination, Fertility Surgery, Fertility Drugs, Others), Establishment (Fertility Clinics, Hospitals, Research Banks), By Region, By Country (2012-2022)
    Published: 12-Dec-2017        Price: US 2400 Onwards        Pages: 224
    Executive Summary A comprehensive research report published in December 2017, through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global  Infertility Treatment Market By Procedure (Assisted Reproductive Technique, Artificial Insemination, Fertility Surgery, Fertility Drugs, Other Procedures), By ART Type (IVF, ICSI, Other Procedure), Analysis By Patient Type ......
  • Global Gout Therapeutics Market Size, Status and Forecast 2022
    Published: 11-Dec-2017        Price: US 3300 Onwards        Pages: 113
    This report studies the global Gout Therapeutics market, analyzes and researches the Gout Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - AstraZeneca - Takeda Pharmaceuticals - Horizon Pharma - Merck - Novartis - Sanofi - GlaxoSmithKline - Eli Lilly - Boehringer Ingelheim - Novo Nordisk - LG Life Sc......
  • Global Musculoskeletal Disorders Therapeutics Market Size, Status and Forecast 2022
    Published: 08-Dec-2017        Price: US 3300 Onwards        Pages: 107
    This report studies the global Musculoskeletal Disorders Therapeutics market, analyzes and researches the Musculoskeletal Disorders Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Pfizer - AbbVie - Johnson & Johnson - Sanofi - Merck - Novartis - Eli Lilly - AstraZeneca - Boehringer Ingelheim - F. Hoffmann-......
  • Global and Regional Varicose Vein Treatment Market Research Report 2017
    Published: 08-Dec-2017        Price: US 3500 Onwards        Pages: 130
    Summary There are several treatment options for Varicose Veins, wearing support stockings, Varicose Vein Treatment Devices; endogenous laser treatment, radiofrequency occlusion, surgery, and lasers and intense pulsed light. Mentioning medical devices for treating Varicose Veins, there is mainly Laser devices, Trivex and RFITT system. Market Segment as follows: By Region - Asia-Pacific - North America - Europe - South Americ......
  • Global Venous Thromboembolism Therapeutics Market Size, Status and Forecast 2022
    Published: 06-Dec-2017        Price: US 3300 Onwards        Pages: 101
    This report studies the global Venous Thromboembolism Therapeutics market, analyzes and researches the Venous Thromboembolism Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Johnson & Johnson - Sanofi - Boehringer Ingelheim - Daiichi Sankyo - Bristol-Myers Squibb (BMS) - Bayer HealthCare - Pfizer - Leo Pharma - P......
  • China Substance Abuse Treatment Market Research Report 2017
    Published: 05-Dec-2017        Price: US 3400 Onwards        Pages: 99
    The global Substance Abuse Treatment market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. China plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2022, with a CAGR of xx%. This report studies the Substance Abuse Treatment development status and future trend in China, focuses on top players in China, also s......
  • United States Brachytherapy Afterloaders, Brachytherapy Seeds Market Report 2017
    Published: 27-Nov-2017        Price: US 3800 Onwards        Pages: 100
    In this report, the United States Brachytherapy Afterloaders, Brachytherapy Seeds market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), ......
  • Global Substance Abuse Treatment Market Professional Survey Report 2017
    Published: 24-Nov-2017        Price: US 3500 Onwards        Pages: 108
    This report studies Substance Abuse Treatment in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Alkermes - Allergan - GSK - Pfizer - Accord Healthc......
  • Global Neuromodulation Market Size, Status and Forecast 2022
    Published: 24-Nov-2017        Price: US 3300 Onwards        Pages: 97
    This report studies the global Neuromodulation market, analyzes and researches the Neuromodulation development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Medtronic, Inc. (U.S.) - Boston Scientific Corporation (U.S.) - St. Jude Medical, Inc. (U.S.) - Synapse Biomedical, Inc. (U.S.) - Nevro Corporation (U.S.) - Neurosigma, Inc. (U.S.) - Neuropace,......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs